AU022751 Inhibitors

Chemical inhibitors of the EZH inhibitory protein (EZIP) operate through a variety of mechanisms to impede the protein's function in epigenetic regulation, particularly concerning the methylation of histone H3 on lysine 27 (H3K27). Compounds such as UNC1999, GSK126, EPZ-6438 (Tazemetostat), CPI-1205, EI1, EPZ005687, PF-06821497, DS-3201b (Valemetostat), and PFI-2 directly target EZH2, the catalytic subunit of the polycomb repressive complex 2 (PRC2) that EZIP is known to interact with. By inhibiting EZH2, these compounds reduce the trimethylation of H3K27, a key epigenetic process that EZIP influences. The inhibition of EZH2 leads to a consequent decrease in the PRC2 complex's ability to silence gene expression, which is a critical aspect of EZIP's regulatory role.

Other inhibitors, such as MAK683 and A-395, do not target EZH2 directly but rather inhibit other components of the PRC2 complex, such as the EED subunit. MAK683 disrupts the PRC2 complex by binding to EED, thereby affecting the complex's functional integrity and influencing the epigenetic regulation driven by EZIP. A-395, as an allosteric inhibitor, also targets EED and hinders the ability of the PRC2 complex to mediate its epigenetic effects, which includes the modulation by EZIP. Additionally, compounds like MS023 inhibit protein arginine methyltransferases (PRMTs), which participate in methylation processes that can intersect with the pathways EZIP is involved in. By inhibiting these PRMTs, MS023 alters the methylation balance within the cell, affecting the regulatory scope of EZIP in histone modification. In summary, these chemical inhibitors collectively disrupt the interaction and influence of EZIP with the PRC2 complex or related methylation pathways, thereby inhibiting the role of EZIP in the regulation of gene expression through histone modification.